Skip to main content
Fig. 7 | BMC Nephrology

Fig. 7

From: Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Fig. 7

Mean ± SD of changes in serum cystatin C (final evaluation point – R20): As shown in Table 6, the 120 μg group showed a tendency and the 240 μg group showed significant inhibition of the increase in change in serum cystatin C as compared with the placebo group (P = 0.0928, 0.0285, respectively), assessed by ANCOVA with the SCr (R20) as covariate

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us